A Sharif

Summary

Affiliation: University Hospital Birmingham
Country: UK

Publications

  1. pmc Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (3C) study: background, rationale, and study protocol
    Richard Haynes
    Clinical Trial Service Unit and Epidemiological Studies Unit, Richard Doll Building, Old Road Campus, Roosevelt Drive, Headington Oxford OX3 7LF, UK
    Transplant Res 2:7. 2013
  2. doi request reprint Unspecified kidney donation--a review of principles, practice and potential
    Adnan Sharif
    Department of Nephrology and Transplantation, Renal Institute of Birmingham, Queen Elizabeth Hospital, Birmingham, United Kingdom
    Transplantation 95:1425-30. 2013
  3. doi request reprint Metformin for patients with diabetes and concomitant renal restrictions--is there an evidence base?
    A Sharif
    Department of Nephrology and Transplantation, Renal Institute of Birmingham, Queen Elizabeth Hospital, Mindelsohn Way, Edgbaston, Birmingham, UK
    QJM 106:291-4. 2013
  4. doi request reprint Incompatible kidney transplantation: a brief overview of the past, present and future
    A Sharif
    Renal Institute of Birmingham, Queen Elizabeth Hospital, Edgbaston, Mindelsohn Way, Birmingham, B15 2WB, UK
    QJM 105:1141-50. 2012
  5. doi request reprint Should metformin be our antiglycemic agent of choice post-transplantation?
    A Sharif
    Renal Institute of Birmingham, Queen Elizabeth Hospital, Birmingham, UK
    Am J Transplant 11:1376-81. 2011

Collaborators

  • N Alachkar
  • Richard Haynes
  • Argiris Asderakis
  • Carmelo Puliatti
  • Alex Baxter
  • Michael Lay
  • Nithya Krishnan
  • Colin Baigent
  • Jonathan Emberson
  • Neil Sheerin
  • Paramit Chowdhury
  • Kathy Jayne
  • Chris Watson
  • Martin Landray
  • Paul Gibbs
  • Will Herrington
  • Chas Newstead
  • James Neuberger
  • Marc Clancy
  • Murat Akyol
  • Chidambaram Nathan
  • Abdul Hammad
  • David Lewis
  • Gareth Jones
  • Sunil Bhandari
  • Keith Rigg
  • Ravi Pararajasingam
  • Peter Friend
  • Sanjay Sinha
  • Iain Macdougall
  • Paul Harden
  • Peter Rowe

Detail Information

Publications5

  1. pmc Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (3C) study: background, rationale, and study protocol
    Richard Haynes
    Clinical Trial Service Unit and Epidemiological Studies Unit, Richard Doll Building, Old Road Campus, Roosevelt Drive, Headington Oxford OX3 7LF, UK
    Transplant Res 2:7. 2013
    ..CNI exposure could be minimized by using more potent induction therapy or alternative maintenance therapy to remove CNIs completely. However, the safety and efficacy of such strategies are unknown...
  2. doi request reprint Unspecified kidney donation--a review of principles, practice and potential
    Adnan Sharif
    Department of Nephrology and Transplantation, Renal Institute of Birmingham, Queen Elizabeth Hospital, Birmingham, United Kingdom
    Transplantation 95:1425-30. 2013
    ..The aim is to highlight the principles, practice, and potential of unspecified kidney donation to bridge the current disparate international practice...
  3. doi request reprint Metformin for patients with diabetes and concomitant renal restrictions--is there an evidence base?
    A Sharif
    Department of Nephrology and Transplantation, Renal Institute of Birmingham, Queen Elizabeth Hospital, Mindelsohn Way, Edgbaston, Birmingham, UK
    QJM 106:291-4. 2013
    ..That is what evidence-based medicine demands and unfortunately is long overdue...
  4. doi request reprint Incompatible kidney transplantation: a brief overview of the past, present and future
    A Sharif
    Renal Institute of Birmingham, Queen Elizabeth Hospital, Edgbaston, Mindelsohn Way, Birmingham, B15 2WB, UK
    QJM 105:1141-50. 2012
    ..It is therefore timely to review the evolution of practice that have led to current desensitization modalities, contrast protocols and outcomes of current regimens and speculate on future direction of incompatible kidney transplantation...
  5. doi request reprint Should metformin be our antiglycemic agent of choice post-transplantation?
    A Sharif
    Renal Institute of Birmingham, Queen Elizabeth Hospital, Birmingham, UK
    Am J Transplant 11:1376-81. 2011
    ....